Stock Price & Analysis

Based on the provided data and context, I'll analyze whether to buy or sell APLS stock.

Technical Analysis: The stock has shown significant weakness, dropping from $26.05 to $25.15 (-3.27%) in the latest trading session. The current price of $25.20 in after-hours shows minimal recovery.

Insider Activity: Recent insider transactions show concerning patterns:

• General Counsel David O. Watson sold 695 shares on January 29, 2025
• Multiple insider sales (46 transactions) in the past 6 months with zero insider purchases

Institutional Activity: There's been mixed institutional interest:

• 134 institutions added positions
• 134 institutions decreased positions This balanced institutional movement suggests uncertainty about the stock's near-term prospects.

Market Sentiment: The stock is showing bearish technical signals with:

• Trading below recent highs
• Increased selling pressure
• Negative price momentum

Conclusion: SELL recommendation at current levels. The combination of:

• Recent price weakness
• Consistent insider selling with no buying
• Mixed institutional sentiment suggests further downside potential in the near term. Investors should consider exiting positions or implementing stop losses.

Based on the provided data and context, I'll analyze APLS stock's price prediction for 2025.

Current Market Position: APLS closed at $25.15 on February 28, 2025, with a trading volume of 2,958,362 shares. The stock experienced a -3.27% decline during regular market hours but showed a slight recovery of +0.20% in post-market trading.

Price Target Analysis for 2025: Based on technical analysis and current market conditions, APLS stock is projected to reach $32-35 by end of 2025, representing a potential upside of 27-39% from current levels, driven primarily by the company's expanding product pipeline and potential market share gains in its therapeutic areas.

Key Drivers for 2025 Price Target: The price target is supported by three main factors:

1. Strong technical support around $24-25 level
2. Positive momentum in biotech sector
3. Company's expanding market presence

Note: This prediction is based on current market conditions and technical analysis. Market conditions can change rapidly, and actual results may vary significantly from these projections.

The S1 support level for APLS Stock is $25.05 ,The R1 resistant level for APLS Stock is $28.6.

As of the end of day on 2025-02-28, the price of APLS Stock was $25.2.

The target price for APLS Stock according to analyst rating is 44.55, with the highest price target at 78.00 and the lowest at 26.00. Analysts have a Moderate Buy rating on APLS Stock overall.

The market cap of APLS is $3.1B.

Based on the provided data and recent market activity, here's a concise analysis of APLS's valuation:

APLS is currently trading at $25.15, showing signs of being fairly valued based on recent market performance and technical indicators. The stock experienced a -3.27% decline in the last regular trading session, with moderate trading volume of 2.96M shares [Relevant Data].

The technical indicators suggest a neutral-to-bearish short-term momentum, with the stock trading below its recent opening price of $26.00 and showing weakness in intraday trading patterns.

Looking at comparable companies in the biotech sector, Apollo (APO) which recently joined the S&P 500, trades at a PE of 20.2x, suggesting the sector is seeing elevated valuations overall.

The stock's recent price action and volume patterns indicate institutional selling pressure, with the stock failing to hold above the $26 resistance level despite positive pre-market movement (+0.15%).

Based on the technical setup and current market conditions, APLS appears to be trading at fair value levels, with limited catalysts for significant near-term appreciation.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Based on the available data and market analysis, here is the price prediction for APLS (Apellis Pharmaceuticals) stock for 2030:

Short-term Technical Analysis

The stock is currently trading at $25.15, showing bearish momentum with RSI at 38.50 indicating oversold conditions. The stock has declined significantly from its previous levels, with the 50-day SMA at $30.16 and 200-day SMA at $33.96.

2030 Price Target Analysis

According to long-term forecasts and growth projections:

• Base case target: $77.21 by 2030
• This represents approximately 207% upside from current levels
• Key growth drivers:
  • Expanding product portfolio in rare diseases
  • Strong revenue growth potential from existing drugs
  • Continued R&D investments in pipeline development

The price target is supported by:

1. Industry growth in rare disease therapeutics market
2. Company's strong intellectual property portfolio
3. Potential for additional drug approvals and market expansion

Key Risks to Consider:

• Clinical trial outcomes
• Regulatory challenges
• Competition in rare disease space
• General market conditions

APLS has a total of 702 employees.